---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-062803"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:44:25.074526+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada terminates esmethadone license agreement with Inturrisi and Manfredi

## Summary
- On July 7, 2025, Relmada delivered termination notice for the esmethadone License Agreement with Drs. Inturrisi and Manfredi.
- The agreement granted exclusive worldwide license for esmethadone in psychiatric use; obligations cease 90 days after notice.
- Relmada had been paying $45,000 quarterly under the agreement; upfront fee of $180,000 paid in 2018.
- The termination ends Relmada's participation in the previously announced esmethadone development program.
- No commercial sales, royalties, or sublicense payments had occurred under the agreement.

## SEC filing metadata
- accession: 0001213900-25-062803
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025062803/0001213900-25-062803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025062803/ea0248503-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-062803
- JSON: https://secwatch.observer/filing/0001213900-25-062803.json
- Plain text: https://secwatch.observer/filing/0001213900-25-062803.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.